Radiotherapy DosageAntineoplastic Combined Chemotherapy ProtocolsIodine RadioisotopesRadiation InjuriesChemotherapy, AdjuvantRadiation DosageRadiation, IonizingCombined Modality TherapyDose-Response Relationship, RadiationRadiotherapyRadiation ToleranceTreatment OutcomeRadiationAntineoplastic AgentsCisplatinRadiotherapy, ConformalRadiation OncologyRadiotherapy, Intensity-ModulatedRadiotherapy, AdjuvantRadiation ProtectionRadiation MonitoringDose FractionationDoxorubicinCyclophosphamideNeoplasm StagingDisease-Free SurvivalBreast NeoplasmsNeoplasm Recurrence, LocalSurvival AnalysisRadiotherapy Planning, Computer-AssistedSurvival RateNeoadjuvant TherapyRadiation PneumonitisPrognosisBrachytherapyLung NeoplasmsRadiometryDrug Administration ScheduleEtoposideBrain NeoplasmsNeoplasmsNeoplasms, Radiation-InducedCranial IrradiationFollow-Up StudiesRadiation Injuries, ExperimentalTime FactorsRadiation-Sensitizing AgentsRadiosurgeryCarboplatinHead and Neck NeoplasmsMethotrexatePaclitaxelGamma RaysVinblastineAdenocarcinomaCosmic RadiationChemoradiotherapyCarcinoma, Squamous CellRadiotherapy, Computer-AssistedBleomycinCarcinoma, Non-Small-Cell LungHodgkin DiseaseRadiotherapy, High-EnergyInduction ChemotherapySalvage TherapyRadiotherapy, Image-GuidedDacarbazineParticle AcceleratorsRadiation-Protective AgentsAntineoplastic Agents, AlkylatingAntimetabolites, AntineoplasticTomography, X-Ray ComputedDeoxycytidineTaxoidsRadiodermatitisNeoplasm MetastasisIfosfamideBackground RadiationDrug Resistance, NeoplasmProspective StudiesActuarial AnalysisOrgans at RiskOrganoplatinum CompoundsKaplan-Meier EstimateClinical Trials as TopicCobalt RadioisotopesSarcomaLymphoma, Non-HodgkinBone NeoplasmsCell Line, TumorLomustineProstatic NeoplasmsUltraviolet RaysMastectomy, SegmentalAntineoplastic Agents, PhytogenicRadiation EffectsPalliative CareNeoplasms, Second PrimaryCytarabineAnthracyclines